清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis

医学 养生 中性粒细胞减少症 顺铂 白细胞减少症 紫杉醇 化疗 内科学 转移 胃肠病学 癌症 发热性中性粒细胞减少症 毒性 肿瘤科
作者
Daisuke Kobayashi,Hironori Ishigami,Mitsuro Kanda,Chie Tanaka,Hironori Yamaguchi,Joji Kitayama,Yasuhiro Kodera
出处
期刊:Oncology [Karger Publishers]
卷期号:98 (1): 48-52 被引量:6
标识
DOI:10.1159/000502484
摘要

<b><i>Introduction:</i></b> Intraperitoneal (IP) chemotherapy is a promising treatment option for gastric cancer (GC) with peritoneal metastasis (PM). Recently, superiority of IP administration of paclitaxel (PTX) combined with S-1 and intravenous PTX over conventional systemic chemotherapy was suggested in a phase III study, although the difference in overall survival did not reach statistical significance in the primary analysis. Thus, attempts to combine IP PTX with other systemic therapies with higher efficacy are warranted. We designed a new regimen combining IP PTX with S-1 plus cisplatin (SP), which is regarded as the standard first-line treatment for metastatic GC in Japan, and subsequently carried out a dose-escalation study. <b><i>Methods:</i></b> The combination was a 5-weekly regimen. IP PTX was to be administered on days 1, 8, and 22 with an initial dose of 15 mg/m<sup>2</sup> at level 1 and 20 mg/m<sup>2</sup> at level 2. S-1 was to be administered orally at a fixed dose of 80 mg/m<sup>2</sup> b.i.d. for 21 days followed by a ­14-day rest. Cisplatin was to be administered intravenously at a dose of 60 mg/m<sup>2</sup> on day 8. Dose-limiting toxicities (DLTs) were defined as grade 4 leukopenia, grade 3 (G3) febrile neutropenia, G3 thrombocytopenia, and G3 nonhematological toxicity. <b><i>Results:</i></b> A total of 9 patients with macroscopic PM were enrolled. No DLTs were observed among the 3 patients at level 1 and 6 patients at level 2. No adverse events or technical problems associated with the IP administration were observed. Consequently, the maximum-tolerated dose was not reached, and the dose for further clinical trials of IP PTX was determined as 20 mg/m<sup>2</sup>. As for efficacy, peritoneal lavage cytology turned negative after the first course in 4 of 7 patients who had positive cytology before treatment. <b><i>Conclusion:</i></b> The present study determined the dose for further clinical trials of IP PTX to be 20 mg/m<sup>2</sup>, when combined with the 5-weekly SP regimen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丰富的亦寒完成签到,获得积分10
7秒前
24秒前
Hqing完成签到 ,获得积分10
43秒前
49秒前
一指墨发布了新的文献求助10
53秒前
JamesPei应助科研通管家采纳,获得10
59秒前
luo完成签到,获得积分10
1分钟前
楚科研完成签到 ,获得积分10
1分钟前
卓初露完成签到 ,获得积分0
1分钟前
as完成签到 ,获得积分10
1分钟前
喜悦的唇彩完成签到,获得积分10
2分钟前
羞涩的傲菡完成签到,获得积分10
2分钟前
2分钟前
蓝意完成签到,获得积分0
2分钟前
迷茫的一代完成签到,获得积分10
3分钟前
哈哈哈完成签到,获得积分10
3分钟前
默默无闻完成签到 ,获得积分10
3分钟前
assiance发布了新的文献求助10
3分钟前
lily完成签到 ,获得积分10
3分钟前
成就的香菇完成签到,获得积分10
3分钟前
噫吁嚱完成签到 ,获得积分10
4分钟前
螺丝炒钉子完成签到,获得积分10
4分钟前
4分钟前
老戎完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
androabo发布了新的文献求助30
4分钟前
智者雨人完成签到 ,获得积分10
4分钟前
4分钟前
标致初曼完成签到,获得积分10
5分钟前
钟山完成签到,获得积分10
5分钟前
5分钟前
Nina完成签到 ,获得积分10
5分钟前
少年与梦发布了新的文献求助10
5分钟前
merrylake完成签到 ,获得积分10
5分钟前
汉堡包应助颜林林采纳,获得10
6分钟前
鸡鸡大魔王完成签到,获得积分10
6分钟前
传奇3应助少年与梦采纳,获得10
6分钟前
机智的苗条完成签到,获得积分10
6分钟前
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
卤化钙钛矿人工突触的研究 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Malcolm Fraser : a biography 700
Handbook of Optical Systems,Volume 6:Advanced Physical Optics 666
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6515520
求助须知:如何正确求助?哪些是违规求助? 8308657
关于积分的说明 17757231
捐赠科研通 5617543
什么是DOI,文献DOI怎么找? 2925057
邀请新用户注册赠送积分活动 1902049
关于科研通互助平台的介绍 1763427